These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10301494)

  • 1. Design, monitoring, and analysis issues relative to adverse events.
    Peace KE
    Drug Inf J; 1987; 21(1):21-8. PubMed ID: 10301494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rethinking statistical approaches to evaluating drug safety.
    Liu JP
    Yonsei Med J; 2007 Dec; 48(6):895-900. PubMed ID: 18159580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products.
    Njue C
    Biologicals; 2011 Sep; 39(5):266-9. PubMed ID: 21807534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of drugs used in fertility regulation.
    Siemens AJ
    Hum Reprod; 1986 Sep; 1(6):405-10. PubMed ID: 3104401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The case for recording events in clinical trials.
    Skegg DC; Doll R
    Br Med J; 1977 Dec; 2(6101):1523-4. PubMed ID: 338116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data on drugs and adverse experiences: moving from the specific to the general.
    Windhorst DB; Pun EF; Zubkoff LA
    Drug Inf J; 1987; 21(1):39-46. PubMed ID: 10301495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals.
    Naito S; Furuta S; Yoshida T; Kitada M; Fueki O; Unno T; Ohno Y; Onodera H; Kawamura N; Kurokawa M; Sagami F; Shinoda K; Nakazawa T; Yamazaki T
    J Toxicol Sci; 2007 Oct; 32(4):329-41. PubMed ID: 17965548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of drugs after marketing.
    J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114
    [No Abstract]   [Full Text] [Related]  

  • 9. Statistical analyses of adverse event data from clinical trials. Special emphasis on serious events.
    O'Neill RT
    Drug Inf J; 1987; 21(1):9-20. PubMed ID: 10281640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basic strategy for avoiding drug interaction during stage of drug development; proposals relative to planning of non-clinical and clinical studies and how clinical trials should be planned.
    Horie T; Nakata H; Kusube K
    J Toxicol Sci; 1996 Dec; 21(5):331-9. PubMed ID: 9035046
    [No Abstract]   [Full Text] [Related]  

  • 11. A problem-oriented approach to safety issues in drug development and beyond.
    Haas JF
    Drug Saf; 2004; 27(8):555-67. PubMed ID: 15154827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human volunteer studies in consumer product research.
    Mensinga TT; Meulenbelt J
    Neth J Med; 1998 Apr; 52(4):129-30. PubMed ID: 9646620
    [No Abstract]   [Full Text] [Related]  

  • 13. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises.
    Corrigan OP
    Soc Sci Med; 2002 Aug; 55(3):497-507. PubMed ID: 12144155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues in the design of clinical trials for safety in HIV-infected children.
    Lindsey JC; Kline MW
    Pediatr AIDS HIV Infect; 1996 Apr; 7(2):69-82. PubMed ID: 11361484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing surveillance of adverse drug reactions in general practice. I: search for new methods.
    Inman WH
    Br Med J (Clin Res Ed); 1981 Apr; 282(6270):1131-2. PubMed ID: 6786470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian methods for design and analysis of safety trials.
    Price KL; Xia HA; Lakshminarayanan M; Madigan D; Manner D; Scott J; Stamey JD; Thompson L
    Pharm Stat; 2014; 13(1):13-24. PubMed ID: 23897858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some observations on the collection of medical event data.
    Mohberg NR
    Drug Inf J; 1987; 21(1):55-62. PubMed ID: 10301497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The assessment of adverse drug reactions in clinical trials.
    Petrie WM; Levine J
    Int Pharmacopsychiatry; 1978; 13(4):209-16. PubMed ID: 730486
    [No Abstract]   [Full Text] [Related]  

  • 19. A prospectively planned cumulative meta-analysis applied to a series of concurrent clinical trials.
    Whitehead A
    Stat Med; 1997 Dec; 16(24):2901-13. PubMed ID: 9483722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How to improve drug development and utilization in pediatrics].
    Pons G; Lassale C; Eschwege E
    Therapie; 1999; 54(4):423-32. PubMed ID: 10667109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.